For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their ...
In addition to their weight loss benefits, GLP-1 RAs also act on neural circuits involved in appetite, impulse control, and ...
GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. On Jan. 13, the FDA ...
GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.
Glucagon-like peptide-1 receptor agonists (GLP-1s) are a class of medication that includes Ozempic®, Wegovy®, and Saxenda®. Some GLP-1s are diabetes drugs, but you can also take a GLP-1 for weight ...
Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...
GLP-1 drugs can suppress thirst cues, leading to dehydration exacerbated by side effects like nausea and diarrhea. There's an ...
In a new trial, people who switched to the experimental daily GLP-1 pill orforglipron were able to keep off most of the weight they had lost taking Wegovy or Zepbound. People who switched from Wegovy ...
The cost of the popular weight loss drugs is pushing up premiums for city employees. The city and its unions should work out a deal to limit, but not end, coverage.
Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost, Axios reported Feb. 16. The ...
Asia has lagged the West on GLP‑1 weight‑loss drugs, but rising obesity, cheaper generics and supportive health systems in ...
The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce. Many drugs offer comparable weight loss. Healthcare companies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results